Julie Cherrington, Ph.D.
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Julie Cherrington, Ph.D. is a life science executive with over 25 years of experience advancing drugs into and through clinical development and to commercialization. She has played a key role in the successful development of several FDA-approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.
Dr. Cherrington has served as President and Chief Executive Officer of Arch Oncology since joining the Company in 2017. Previously, she served as President and Chief Executive Officer at Revitope, also an immune-oncology company, at Zenith Epigenetics, a bromodomain inhibitor company, and at Pathway Therapeutics, an oncology and inflammation company. Earlier in her career, she served as Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility.
Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.
Daniel Pereira, Ph.D.
CHIEF SCIENTIFIC OFFICER
Daniel Pereira, Ph.D. has over 20 years of experience in the biotechnology and pharmaceutical industries. He has contributed to R&D initiatives resulting in approximately 100 oncology biologic drug candidates, including mono/bispecific antibodies, ADCs and Immuno-oncology candidates, as well as in four FDA-approved products – Erbitux®, Cyramza™, Portrazza® and Lartruvo®.
Dr. Pereira serves as Chief Scientific Officer of Arch Oncology. Prior to joining Arch, he served as Vice President, Discovery Research for six years at Agensys Inc., an affiliate of Astellas Pharmaceuticals Inc. In addition, he served as Site Head and Vice President, Research for four years at Roche/Arius, Hoffmann-La Roche Limited. Dr. Pereira began his career as Director Tumor Biology at ImClone Systems, Inc., where he served for eight years.
Dr. Pereira received a B.S. with honors in biochemistry and a M.S. in chemistry from the University of Manitoba. He earned a Ph.D. in biology and received his doctorate training with Dr. Frank Graham at McMaster University. He received his post-doctoral training with Dr. John Dick at the University of Toronto.
Jackie Walling, MBChB, Ph.D.
CHIEF MEDICAL OFFICER
Jackie Walling, MBChB, Ph.D. has over 25 years of experience in the global clinical development of drugs for treating patients with cancer. She has provided leadership to clinical development programs leading to the successful FDA approval of several drugs, including Gemzar™, ALIMTA®, Vimizim™, PALYNZIQ™, and TALZENNA®.
Dr. Walling serves as Chief Medical Officer of Arch Oncology. She has extensive experience serving as a Chief Medical Officer for clients. She previously has served as Vice President of Clinical Development for BioMarin Pharmaceutical Inc., leading the Company’s global clinical development. Earlier in her career, Dr. Walling was Vice President, Clinical Research for Axys Pharmaceuticals, Inc. and Medical Director for Tularik, Inc. Dr. Walling began her pharmaceutical career at Eli Lilly and Company, where she worked for a decade in the United Kingdom and the United States in roles of increasing responsibility for several of the Company’s oncology drug development programs.
Dr. Walling received a B.Sc. in biology and Ph.D. from the University of Southampton, UK. She received her post-doctoral training in cancer research from Aston University, UK. She earned an MBChB (M.D. equivalent) with honors from the University of Bristol, UK, and practiced medicine in the UK.
Vicki Sung, Ph.D.
VICE PRESIDENT OF TRANSLATIONAL MEDICINE
Dr. Sung has 20 years of oncology drug development experience, spanning from target discovery and validation through pharmacology and late-stage clinical development.
Dr. Sung serves as Vice President of Translational Medicine at Arch Oncology. Prior to joining Arch, she led translational efforts for hematology and oncology programs for ten years at Celgene, where she helped advance drugs from IND through Phase 3 clinical trials, including the clinical development of Luspatercept, that supported an NDA submission to the FDA. Previously, Dr. Sung held R&D positions at Novartis (Chiron) and Sugen (Pharmacia/Pfizer), where she contributed to the validation and development of both small molecules and biologics.
Dr. Sung holds a B.S. in integrative biology from the University of California, Berkeley and an M.S. in biology from Georgetown University. She earned a Ph.D. in cell biology from the Georgetown University School of Medicine and completed postdoctoral studies in endocrinology at Stanford University School of Medicine.
William A. Frazier, Ph.D.
Co-founder and Scientific Advisor
William Frazier, Ph.D. co-founded the Company based on research from his laboratory and from the National Institutes of Health. He discovered that CD47 is a receptor for thrombospondin-1 and has been a leader in the field of CD47-mediated signaling pathways, contributing to over 140 publications. Dr. Frazier is a professor of Biochemistry, Molecular Biophysics, and Cell Biology at Washington University School of Medicine.
Pamela T. Manning, Ph.D.
Co-founder and Scientific Advisor
Pamela Manning, Ph.D. co-founded the Company and served as Vice President of Research until 2018. She has extensive expertise in pharmacology, spanning multiple therapeutic areas including neuroscience, cardiovascular, oncology, inflammation and pain. Previously, she served as Director, Inflammation Pharmacology at Pfizer.
Robert Karr, M.D.
Robert Karr, M.D. serves as an advisor to the Company. He has extensive experience in the pharmaceutical and biotechnology industries. Previously, he served as Chief Executive Officer and Chief Scientific Officer of the Company, Senior Vice President of R&D Strategy at Pfizer, President of Idera Pharmaceuticals, and Vice President of R&D Strategy for Warner-Lambert and G. D. Searle.